title: [Doxazosine associated to renin-angiotensin blockers and calcioantagonists in chronic renal failure patients].
abstract: OBJECTIVE
  To evaluate the safety and effectiveness of the alfa-blocker doxazosin GITS in CRF patients.
  
  
  METHODS
  The study recruited 203 CRF patients (creatinine > 1,4 mg/dl for males, creatinine > 1,2 mg/dl for females, or creatinine clearance < 80 ml/min). All patients were receiving ACE inhibitores (63.4%) or angiotensin II antagonist (36.6%) therapy but they had higher blood pressure than recommended for CRF (130/85 mmHg). Patients were clinically evaluated 1, 3 and 6 moths after starting treatment with lercanidipine (10 mg once daily). Patients with high blood pressure in spite of combined therapy with two drugs added doxazosin GITS 4-8 mg once daily to treatment.
  
  
  RESULTS
  57 patients rendered evaluable for the study (age 64.8 +/- 12.7 years, 47.4% males and 52.6 females). BP significantly decrease from 164 +/- 17/92 +/- 9 mmHg to 135 +/- 13/78 +/- 8 mmHg. 67.6% patients showed a significant BP reduction and 32.4% gets optimal BP control (< 130/85 mmHg). Two patients (3.6%) showed untoward effects. No biochemical changes were detected.
  
  
  CONCLUSIONS
  Doxazosin showed a good antihypertensive effect in CRF patients when used as third drug in resistant severe hypertension. It has a good tolerability profile and showed a neutral profile on biochemical parameters.
authors.affiliation: Hospital Infanta Cristina, Badajoz. nroblesp@meditex.es
authors.forename: N R
authors.initials: NR
authors.lastname: Robles
authors.forename: F
authors.initials: F
authors.lastname: Gómez Campderá
authors.forename: I
authors.initials: I
authors.lastname: Ocón
authors.forename: M
authors.initials: M
authors.lastname: Manjón
authors.forename: L
authors.initials: L
authors.lastname: Pastors
authors.forename: J
authors.initials: J
authors.lastname: Herrera
authors.forename: J
authors.initials: J
authors.lastname: Villatoro
authors.forename: I
authors.initials: I
authors.lastname: Calls
authors.forename: I
authors.initials: I
authors.lastname: Torrijos
authors.forename: I
authors.initials: I
authors.lastname: Rodríguez Villareal
authors.forename: M A
authors.initials: MA
authors.lastname: Rodríguez Martínez
authors.forename: M L
authors.initials: ML
authors.lastname: Méndez
authors.forename: A
authors.initials: A
authors.lastname: Morey
authors.forename: I
authors.initials: I
authors.lastname: Martínez Fernández
authors.forename: I
authors.initials: I
authors.lastname: Marco
authors.forename: A
authors.initials: A
authors.lastname: Liébana
authors.forename: B
authors.initials: B
authors.lastname: Rincón
authors.forename: F
authors.initials: F
authors.lastname: Tornero
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D017292:Doxazosin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D006973:Hypertension / Q000150:complications* / Q000188:drug therapy*; D007676:Kidney Failure, Chronic / Q000150:complications* / Q000188:drug therapy*; D008297:Male
chemical_list: D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D017292:Doxazosin